MXPA04000041A - Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. - Google Patents
Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4.Info
- Publication number
- MXPA04000041A MXPA04000041A MXPA04000041A MXPA04000041A MXPA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compounds
- vla
- cell
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a derivados novedosos de imidazolidina de la formula (I), en donde B, E, W, Y, R, R2, R3, R30, e y h tienen los significados indicados en las reivindicaciones. Los compuestos de la formula (I) son compuestos farmaceuticos que son adecuados, por ejemplo, para el tratamiento de enfermedades inflamatorias como por ejemplo artritis reumatoide, o enfermedades alergicas. Los compuestos de la formula (I) son inhibidores de la adhesion y migracion de leucocitos y/o antagonistas de receptor de adhesion VLA-4, que pertenece al grupo de las integrinas. Son adecuados, en general, para tratar enfermedades causadas o asociadas con un grado indeseable de adhesion de leucocitos y/o migracion de leucocitos o en las cuales las interacciones celula-celula o celula-matriz, basadas en las interacciones de receptores VLA-4 con sus ligandos, desempenan una funcion. La invencion se refiere ademas a procedimientos para la preparacion de los compuestos (I), a su uso y a preparaciones farmaceuticas que comprenden compuestos de la formula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10137595A DE10137595A1 (de) | 2001-08-01 | 2001-08-01 | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
PCT/EP2002/008106 WO2003011288A1 (en) | 2001-08-01 | 2002-07-20 | Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04000041A true MXPA04000041A (es) | 2004-05-21 |
Family
ID=7693930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04000041A MXPA04000041A (es) | 2001-08-01 | 2002-07-20 | Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. |
Country Status (30)
Country | Link |
---|---|
US (1) | US6962937B2 (es) |
EP (1) | EP1414444B1 (es) |
JP (1) | JP4676697B2 (es) |
KR (1) | KR100910930B1 (es) |
CN (1) | CN1537000B (es) |
AR (1) | AR036349A1 (es) |
AT (1) | ATE391504T1 (es) |
AU (1) | AU2002328931B2 (es) |
BR (1) | BR0211535A (es) |
CA (1) | CA2455966C (es) |
CO (1) | CO5550452A2 (es) |
DE (2) | DE10137595A1 (es) |
DK (1) | DK1414444T3 (es) |
ES (1) | ES2301673T3 (es) |
HK (1) | HK1066166A1 (es) |
HR (1) | HRP20040108A2 (es) |
HU (1) | HUP0401406A3 (es) |
IL (2) | IL160093A0 (es) |
MX (1) | MXPA04000041A (es) |
MY (1) | MY133467A (es) |
NO (1) | NO326696B1 (es) |
NZ (1) | NZ530887A (es) |
PE (1) | PE20030348A1 (es) |
PL (1) | PL365396A1 (es) |
PT (1) | PT1414444E (es) |
RS (1) | RS6104A (es) |
RU (1) | RU2318815C2 (es) |
TW (1) | TWI325863B (es) |
WO (1) | WO2003011288A1 (es) |
ZA (1) | ZA200400194B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4617449B2 (ja) | 2002-07-11 | 2011-01-26 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するn−ヒドロキシアミド誘導体 |
EP2093218A1 (en) * | 2008-02-22 | 2009-08-26 | Ruggero Fariello | Arylalkyl substituted imidazolidinones |
US20090275529A1 (en) * | 2008-05-05 | 2009-11-05 | Reiss Allison B | Method for improving cardiovascular risk profile of cox inhibitors |
EP2632492B1 (en) | 2010-10-25 | 2017-10-04 | Biogen MA Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE235866C (es) | ||||
DE4009506A1 (de) | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
DE4126277A1 (de) | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
JPH07506091A (ja) | 1992-01-13 | 1995-07-06 | バイオゲン インコーポレイテッド | 喘息の処置 |
JPH07506566A (ja) | 1992-02-12 | 1995-07-20 | バイオゲン インコーポレイテッド | 炎症性胃腸病の処置 |
DE4207254A1 (de) | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
DE4213634A1 (de) | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
DE4224414A1 (de) | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
DE4228717A1 (de) | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
EP0677060A1 (en) | 1993-01-08 | 1995-10-18 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
ATE161730T1 (de) | 1993-02-09 | 1998-01-15 | Biogen Inc | Antikörper zur behandlung von insulinabhängigen diabetes |
DE4308034A1 (de) | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
CN1211123C (zh) | 1994-01-25 | 2005-07-20 | 雅典娜神经科学公司 | 抗白细胞粘附分子vla-4的人源化抗体 |
WO1996000581A1 (en) | 1994-06-29 | 1996-01-11 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
ES2171768T3 (es) * | 1996-03-20 | 2002-09-16 | Hoechst Ag | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. |
SG124234A1 (en) | 1996-07-25 | 2006-08-30 | Biogen Idec Inc | Cell adhesion inhibitors |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AU748041B2 (en) | 1997-10-31 | 2002-05-30 | Aventis Pharma Limited | Substituted anilides |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
AU3716499A (en) | 1998-04-21 | 1999-11-08 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
BR9911701A (pt) | 1998-06-30 | 2001-03-20 | Pfizer Prod Inc | Inibidores não peptidila da ligação à célula dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias |
WO2000002903A1 (en) | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
-
2001
- 2001-08-01 DE DE10137595A patent/DE10137595A1/de not_active Withdrawn
-
2002
- 2002-07-20 HU HU0401406A patent/HUP0401406A3/hu unknown
- 2002-07-20 IL IL16009302A patent/IL160093A0/xx unknown
- 2002-07-20 AU AU2002328931A patent/AU2002328931B2/en not_active Ceased
- 2002-07-20 BR BR0211535-2A patent/BR0211535A/pt active Search and Examination
- 2002-07-20 CA CA2455966A patent/CA2455966C/en not_active Expired - Fee Related
- 2002-07-20 KR KR1020047001524A patent/KR100910930B1/ko not_active IP Right Cessation
- 2002-07-20 ES ES02764740T patent/ES2301673T3/es not_active Expired - Lifetime
- 2002-07-20 WO PCT/EP2002/008106 patent/WO2003011288A1/en active IP Right Grant
- 2002-07-20 PT PT02764740T patent/PT1414444E/pt unknown
- 2002-07-20 MX MXPA04000041A patent/MXPA04000041A/es active IP Right Grant
- 2002-07-20 EP EP02764740A patent/EP1414444B1/en not_active Expired - Lifetime
- 2002-07-20 AT AT02764740T patent/ATE391504T1/de active
- 2002-07-20 NZ NZ530887A patent/NZ530887A/en not_active IP Right Cessation
- 2002-07-20 DE DE60226032T patent/DE60226032T2/de not_active Expired - Lifetime
- 2002-07-20 CN CN028151046A patent/CN1537000B/zh not_active Expired - Fee Related
- 2002-07-20 RU RU2004105966/04A patent/RU2318815C2/ru not_active IP Right Cessation
- 2002-07-20 PL PL02365396A patent/PL365396A1/xx not_active Application Discontinuation
- 2002-07-20 DK DK02764740T patent/DK1414444T3/da active
- 2002-07-20 RS YU6104A patent/RS6104A/sr unknown
- 2002-07-20 JP JP2003516518A patent/JP4676697B2/ja not_active Expired - Fee Related
- 2002-07-26 PE PE2002000672A patent/PE20030348A1/es not_active Application Discontinuation
- 2002-07-30 MY MYPI20022873A patent/MY133467A/en unknown
- 2002-07-30 AR ARP020102868A patent/AR036349A1/es active IP Right Grant
- 2002-07-30 TW TW091116941A patent/TWI325863B/zh not_active IP Right Cessation
- 2002-07-31 US US10/208,182 patent/US6962937B2/en not_active Expired - Lifetime
-
2004
- 2004-01-12 ZA ZA200400194A patent/ZA200400194B/xx unknown
- 2004-01-26 CO CO04005444A patent/CO5550452A2/es not_active Application Discontinuation
- 2004-01-27 IL IL160093A patent/IL160093A/en not_active IP Right Cessation
- 2004-01-30 NO NO20040426A patent/NO326696B1/no not_active IP Right Cessation
- 2004-01-30 HR HR20040108A patent/HRP20040108A2/hr not_active Application Discontinuation
- 2004-11-18 HK HK04109104.0A patent/HK1066166A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE455788T1 (de) | Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
MY118313A (en) | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
MY118176A (en) | Heterocycles as inhibitors of leucocyte adhesion and as vla-4-antagonists | |
MY123865A (en) | Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists | |
MX9708782A (es) | Heterociclos de 5 anillos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4. | |
Mishra et al. | Anti‐HIV activity of thiosemicarbazone and semicarbazone derivatives of (±)‐3‐menthone | |
MY121745A (en) | 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them. | |
TNSN04199A1 (en) | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
BR9610422A (pt) | Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina | |
US20030004189A1 (en) | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | |
TR199801870A2 (xx) | Yeni 5-halka-heterosiklenler, bunlar�n �retimi, bunlar�n kullan�m�. | |
WO2002014281A8 (en) | Pyridine derivatives as inhibitors of p38 | |
MA29258B1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
MXPA04000041A (es) | Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. | |
YU70803A (sh) | Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa | |
TR200103856T2 (tr) | Naftiridin türevleri, bunların preparasyon işlemleri, kullanımları ve farmasötik kompozisyonlar. | |
TWI256386B (en) | Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
SG146692A1 (en) | Melanin concentrating hormone antagonists | |
TR200103858T2 (tr) | Hücre yapışmasının önleyicileri olarak ikame edilmiş purin türevleri | |
MXPA05005340A (es) | Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. | |
WO2008155594A3 (en) | Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof | |
TH42839A (th) | เฮเทอโรไซเคิลชนิด 5 เมมเบอร์ริงชนิดใหม่, การเตรียมสารเหล่านั้น, การใช้สารเหล่านั้นและยาเตรียมทางเภสัชศาสตร์ที่ประกอบด้วยสารเหล่านั้น |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status | ||
FG | Grant or registration |